Single-Center Experience and Literature Review of Radiotherapy Outcomes for Adult Ependymomas

Abstract

Objective: To retrospectively determine the long-term outcome of adult intracranial and spinal ependymoma patients treated with postoperative radiation therapy after surgery. Methods: Fourteen adult patients who underwent radiotherapy after surgery at a single center between 1999 and 2022 were included. The endpoints analyzed were overall survival and progression-free survival, together with prognostic factors. Results: The median (range) age was 29.5 (23–58) years. The majority (71.4%) of the tumors were located in the spinal canal and gross total resection was performed in nine (64.3%) patients. Six patients were irradiated after recurrence (spinal n=4, intracranial n=2) of whom three had myxopapillary and two had anaplastic histology. Patients were followed up for a median duration of 106.5 (13-172) months. Overall, 4 patients (intracranial n=3, spinal n=1) had recurrences and died after radiotherapy as a direct result of disease progression during the follow-up period. All of these intracranial tumors exhibited anaplastic histology and the spinal tumor was myxopapillary type. Patients with intracranial lesions had a 5-year survival of 50% and no patient was alive on the 10th year, compared with 5- and 10-year overall survival of 87.5 % for patients with spinal tumors. Patients with spinal tumors had a 5- and 10-year progression-free survival rate of 52.5%, while those with intracranial lesions had a rate of 25%. Conclusion: In low-grade spinal ependymomas radiotherapy appears to control disease, even after recurrence. For myxopapillary ependymoma patients, in subtotally resected intracranial and all high-grade tumors, regardless of the extent of resection, adjuvant radiotherapy should be administered.

Keywords

• ependymoma
• adult
• radiotherapy
• histology

References

1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007 –2011. Neuro Oncol. 2014;16(suppl 4): iv1–i63. doi: 10.1093/neuonc/nou223.
2. McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg. 2009 Apr;110(4):725-729. doi: 10.3171/2008.9.JNS08117.
3. Pajtler KW, Mack SC, Ramaswamy V, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 2017;133(1):5–12. doi: 10.1007/s00401-016-1643-0.
4. Wostrack M, Ringel F, Eicker SO, et al. Spinal ependymoma in adults: a multicenter investigation of surgical outcome and progression-free survival. J Neurosurg Spine. 2018 Jun;28(6):654-662. doi: 10.3171/2017.9.SPINE17494.
5. Zuccato JA, Algan O, Nair VJ, et al. Resection and radiotherapy for intracranial ependymoma: a multi-institutional 50-year experience. J Neurosurg. 2021 Dec 24:1-8. Zuccato JA, Algan O, Nair VJ, et al. Resection and radiotherapy for intracranial ependymoma: a multi-institutional 50-year experience. J Neurosurg. 2021 Dec 24:1-8.
6. Rudà R, Reifenberger G, Frappaz D, et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro Oncol. 2018;20(4):445-456. doi: 10.1093/neuonc/nox166.
7. Nuno M, Yu J.J, Varshneya K, et al. Treatment and survival of supratentorial and posterior fossa ependymomas in adults. J. Clin. Neurosci. 2016, 28, 24–30. doi: 10.1016/j.jocn.2015.11.014.
8. Metellus P, Guyotat J, Chinot O, et al. Adult intracranial WHO grade II ependymomas: Long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro-Oncology 2010, 12, 976–984. doi: 10.1093/neuonc/noq047.

9. Vitanovics D, Bálint K, Hanzély Z, Banczerowski P, Afra D. Ependymoma in adults: surgery, reoperation and radiotherapy for survival. Pathol Oncol Res. 2010 Mar;16(1):93-9. doi: 10.1007/s12253-009-9194-5.
10. Evans AE, Anderson JR, Lefkowitz-Boudreaux IB, Finlay JL. Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study. Med Pediatr Oncol 1996;27:8–14. doi: 10.1002/(SICI)1096-911X(199607)27:1<8::AID-MPO3>3.0.CO;2-K.
11. Erpolat OP, Bora H, Karahacioğlu E, et al. Radiotherapy results of adult ependymoma. Turkish Journal of Oncology, 2012; 27(4). doi: 10.5505/tjoncol.2012.833.
12. Haydaroğlu A, Aras A, Özkök S, Öztop S, Mutluer S. Medulloblastomas and Ependymomas treated with craniospinal radiotherapy. SSK Tepecik Hast Derg 1991; 1 (2) : 13.3 – 6. DOI: 10.5222/terh.1991.85722.
13. Ellison DW, Figarella-Branger D, editors. Chapter 2: Gliomas, glioneuronal tumours, and neuronal tumours- Ependymal tumours. In: WHO Classification of Tumours Editorial Board. Central nervous system tumours. Lyon (France): International Agency for Research on Cancer; 2021. (WHO classification of tumours series, 5th ed.; vol. 6).
14. Hamilton KR, Lee SS, Urquhart JC, Jonker BP. A systematic review of outcome in intramedullary ependymoma and astrocytoma. J Clin Neurosci. 2019 May;63:168-175. doi: 10.1016/j.jocn.2019.02.001.
15. Tsai CJ, Wang Y, Allen PK, et al. Outcomes after surgery and radiotherapy for spinal myxopapillary ependymoma: update of the MD Anderson Cancer Center experience. Neurosurgery. 2014 Sep;75(3):205-14. doi: 10.1227/NEU.0000000000000408.
16. Pesce A, Palmieri M, Armocida D, Frati A, Miscusi M, Raco A. Spinal Myxopapillary Ependymoma: The Sapienza University Experience and Comprehensive Literature Review Concerning the Clinical Course of 1602 Patients. World Neurosurg. 2019 Sep;129:245-253. doi: 10.1016/j.wneu.2019.05.206.
17. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
18. Khalid SI, Adogwa O, Kelly R, et al. Adult Spinal Ependymomas: An Epidemiologic Study. World Neurosurg. 2018 Mar;111:e53-e61. doi: 10.1016/j.wneu.2017.11.165.
19. Wu L, Wang LA, Zou W, Yang J, Jia W, Xu Y. Primary spinal anaplastic ependymoma: A single-institute retrospective cohort and systematic review. Frontiers in Oncology. 2023 Feb 7;13:1083085. doi: 10.3389/fonc.2023.1083085.
20. Pica A, Miller R, Villà S, et al. The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1114-20. doi: 10.1016/j.ijrobp.2008.09.034.
21. Oh MC, Ivan ME, Sun MZ, et al. Adjuvant Radiotherapy Delays Recurrence Following Subtotal Resection of Spinal Cord Ependymomas. Neuro Oncol (2013) 15:08–215. doi: 10.1093/neuonc/nos286.
22. Tarapore PE, Modera P, Naujokas A, et al. Pathology of Spinal Ependymomas: An Institutional Experience Over 25 Years in 134 Patients. Neurosurgery (2013) 73:247–255. doi: 10.1227/01.neu.0000430764.02973.78.
23. Lee S-H, Chung CK, Kim CH, et al. Long-Term Outcomes of Surgical Resection With or Without Adjuvant Radiation Therapy for Treatment of Spinal Ependymoma: A Retrospective Multicenter Study by the Korea Spinal Oncology Research Group. Neuro Oncol (2013) 15:921–929. doi: 10.1093/neuonc/not038.
24. Vera-Bolanos E, Aldape K, Yuan Y, et al. CERN Foundation Clinical Course and Progression-Free Survival of Adult Intracranial and Spinal Ependymoma Patients. Neuro Oncol (2015) 17:440–7. doi: 10.1093/neuonc/nou162.
25. Lin Y, Andrew Jea A, Melkonian SC, Lam S. Treatment of Pediatric Grade II Spinal Ependymomas: A Population-Based Study. J Neurosurg Pediatr (2015) 15:243–9. doi: 10.3171/2014.9.PEDS1473.
26. Keil VC, Schmitt AJ, Martin SC, Cadoux-Hudson TA, Pereira EA. Optimising treatment strategies in spinal ependymoma based on 20 years of experience at a single centre. J Clin Neurosci. 2016 Jul;29:52-8. doi: 10.1016/j.jocn.2016.01.003.
27. Wostrack M, Ringel F, Eicker SO, et al. Spinal ependymoma in adults: a multicenter investigation of surgical outcome and progression-free survival. J Neurosurg Spine. 2018 Jun;28(6):654-662. doi: 10.3171/2017.9.SPINE17494.
28. Wang Y, Cai R, Wang R, et al. Outcome Predictors in the Management of Intramedullary Classic Ependymoma: An Integrative Survival Analysis. Med (Baltimore) (2018) 97:e10870. doi: 10.1097/MD.0000000000010870.
29. Brown DA, Goyal A, Takami H, et al. Radiotherapy in addition to surgical resection may not improve overall survival in WHO grade II spinal ependymomas. Clin Neurol Neurosurg. 2020 Feb;189:105632. doi: 10.1016/j.clineuro.2019.105632.
30. Savoor R, Sita TL, Dahdaleh NS, et al. Long-Term Outcomes of Spinal Ependymomas: An Institutional Experience of More Than 60 Cases. J Neurooncol (2021) 151:241–7. doi: 10.1007/s11060-020-03658-7.
31. Ryu SM, Lee SH, Kim ES, Eoh W. Predicting Survival of Patients with Spinal Ependymoma Using Machine Learning Algorithms with the SEER Database. World Neurosurg. 2019; 124:331-339. doi: 10.1016/j.wneu.2018.12.091.
32. Ramaswamy V, Hielscher T, Mack SC, et al. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. J Clin Oncol. 2016 Jul 20;34(21):2468-77. doi: 10.1200/JCO.2015.65.7825.
33. National Comprehensive Cancer Network. Central nervous system cancers version 1.2023. 2023. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed December 22, 2023.
34. Reni M, Brandes AA, Vavassori V, et al. A Multicenter Study of the Prognosis and Treatment of Adult Brain Ependymal Tumors. Cancer (2004) 100:1221–9. doi: 10.1002/cncr.20074. PMID: 15022290.
35. Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg. 2005 Apr;102(4):629-36. doi: 10.3171/jns.2005.102.4.0629.
36. Metellus P, Barrie M, Figarella-Branger, et al. Multicentric French Study on Adult Intracranial Ependymomas: Prognostic Factors Analysis and Therapeutic Considerations From a Cohort of 152 Patients. Brain (2007) 130:1338–49. doi: 10.1093/brain/awm046. Guyotat J, Metellus P, Giorgi R, et al. Infratentorial Ependymomas: Prognostic Factors and Outcome Analysis in a Multi-Center Retrospective Series of 106 Adult Patients. Acta Neurochir (Wien) (2009) 151:947–60. doi: 10.1007/s00701-009-0417-z.
37. Metellus P, Guyotat J, Chinot O, et al. Adult Intracranial WHO Grade II Ependymomas: Long-Term Outcome and Prognostic Factor Analysis in a Series of 114 Patients. Neuro Oncol (2010)12:976–84. doi: 10.1093/neuonc/noq047.
38. Dützmann S, Schatlo B, Lobrinus A, et al. A Multi-Center Retrospective Analysis of Treatment Effects and Quality of Life in Adult Patients With Cranial Ependymomas. J Neurooncol (2013) 114:319–27. doi: 10.1007/s11060-013-1187-2.
39. Nuño M, Yu JJ, Varshneya K, Alexander J, Mukherjee D, Black KL, Patil CG. Treatment and survival of supratentorial and posterior fossa ependymomas in adults. J Clin Neurosci. 2016 Jun;28:24-30. doi: 10.1016/j.jocn.2015.11.014.
40. Prabhu RS, Corso CD, Ward MC, et al. The effect of adjuvant radiotherapy on overall survival in adults with intracranial ependymoma. Neurooncol Pract. 2020 Jul;7(4):391-399. doi: 10.1093/nop/npz070.
41. Wee CW, Kim IH, Park CK, et al. Postoperative radiotherapy for WHO grade II-III intracranial ependymoma in adults: An intergroup collaborative study (KROG 18-06/KNOG 18-01). Radiother Oncol. 2020 Sep;150:4-11. doi: 10.1093/nop/npz070.
42. Zuccato JA, Algan O, Nair VJ, et al. Resection and radiotherapy for intracranial ependymoma: a multi-institutional 50-year experience. J Neurosurg. 2021 Dec 24:1-8. doi: 10.3171/2021.9.JNS211299.